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Interleukin-23 (IL-23) is considered a critical regulator of IL-17 in lymphocytes. Whereas antibodies targeting
IL-23 ameliorate colitis, IL-17 neutralization exacerbates disease. In this issue, Cua and colleagues and
Maxwell and colleagues show that IL-17 maintains intestinal barrier integrity, helping explain this dichotomy
(Lee et al., 2015; Maxwell et al., 2015).CD4+ T helper (Th) cells orchestrate im-
mune responses primarily by secreting
cytokines that regulate the function and
development of other immune cells, as
well as non-immune cell types. For many
years, the prevailing dogma in the field
was that Th cells fell into two categories:
Th1 cells, which express interferon-g
(IFN-g) and are induced to differentiate
by interleukin-12 (IL-12), and Th2 cells,
which express IL-4 and IL-5 and are
induced by IL-4. A decade ago, the Th1-
Th2 cell paradigm was overhauled to
incorporate the ‘‘Th17’’ cell population,
so named because its signature cytokine
is IL-17 (also known as IL-17A). A key dis-
covery leading to this paradigm shift was
the recognition that IL-23, a heterodimer
that shares its p40 subunit with IL-12, is
required for Th17 cell activity in vivo. The
IL-23-IL-17 axis is now known to play a
pivotal role in protection against infec-
tious microbes, particularly fungi. How-
ever, IL-23 and IL-17 are pathogenic in a
number of autoimmune diseases. Even
prior to the discovery of Th17 cells, efforts
to develop biologic agents targeting
these cytokines were underway in the
pharmaceutical industry. In recent years,
the fruits of this labor have begun to
be realized, with antibodies against the
IL-12-IL-23 p40 subunit (ustekinumab)
in increasingly widespread clinical use.
Antibodies targeting IL-17A (secukinu-
mab) or the IL-17 receptor (brodalumab)
are remarkably effective in psoriasis trials,
and secukinumab was recently approved
for use in moderate to severe plaque pso-
riasis (Sanford and McKeage, 2015).
Inflammatory bowel disease (IBD) is
associated with exacerbated inflamma-
tory responses in the gut. Polymorphisms
in genes encoding components of the
Th17 cell pathway, such as IL23R and620 Immunity 43, October 20, 2015 ª2015 ElSTAT3, are associated with IBD based
on genome-wide association studies
(GWAS). Indeed, elevated amounts of
both IL-23 and IL-17 are detected in IBD
in humans and in mouse models of colitis.
Moreover, ustekinumab or anti-IL-23 Abs
(MEDI2070) alleviate symptoms in pa-
tients with Crohn’s disease (CD) that are
refractory to anti-tumor-necrosis-factor
(TNF) therapy. Therefore, targeting IL-23
in IBD appears to be an effective thera-
peutic strategy.
In surprising contrast, clinical trials of
anti-IL-17A or anti-IL-17RA antibodies in
CD show no improvement or even exacer-
bation of disease (Hueber et al., 2012).
Although disappointing clinically, these
findings are consistent with many (but not
all) mouse models of colitis. For example,
studies using anti-IL-17A treatment or
Il17a/ mice in dextran sodium sulfate
(DSS)-induced intestinal injury or a CD4+
T cell transfermodel of colitis have demon-
strated exacerbated symptoms (O’Connor
et al., 2009;Ogawaet al., 2004;Songet al.,
2015). On the other hand, blockade of IL-
17A reduces pathology in an IL-10-defi-
cient colitogenic setting (Yen et al., 2006).
Broadly speaking, the fidelity of mouse
modelswith respect tohuman IBD remains
controversial.
In this issue of Immunity, Lee et al. and
Maxwell et al. address this dichotomy
between IL-23 and IL-17A in mediating
pathogenesis of IBD. Inflammation at
mucosal surfaces such as gut or lung is
associated with destruction of epithelial
cells that line the tissue, in part due to
breakdown of intercellular tight junctions.
Inflammatory cytokines are major drivers
of this process. In these reports, both
groups came to a similar conclusion that
the dominant function of IL-17 in colitis is
to preserve the intestinal epithelial barrier,sevier Inc.despite the potential of IL-17 to drive path-
ogenic inflammation as it does in many
other autoimmune conditions (Figure 1).
Lee et al., using the DSS model of colitis,
showed that the expression ofmRNA tran-
scripts associated with epithelial tight
junction integrity was not altered in
Il17a/ mice. Rather, they found that the
increased gut permeability in Il17a/
mice was associated with abnormal sub-
cellular localization of the tight junction
protein occludin. Although the molecular
basis for occludin’s altered localization is
unclear, this phenomenon helps explain
the compromise of the epithelial barrier.
The authors further showed that condi-
tional deletion of Traf3ip2 (encoding Act1,
the common IL-17R signaling adaptor) in
intestinal epithelial cells increased gut
permeability during active colitis. These
data are in good agreement with a recent
report by Youcun Qian’s group, who
demonstrate that IL-17A stimulates gut
epithelial cell proliferation and healing
through a cooperative signaling pathway
with the fibroblast growth factor receptor
(FGFR) (Song et al., 2015).
Maxwell et al. took an interesting
approach to the same question by ex-
ploiting a less common colitis mouse
model that accurately reflects the human
response to biologic therapy. Unlike Lee
et al., this group did not see an exacer-
bating effect of anti-IL-17A therapy in
DSS colitis. Although it is unclear why
this was the case, DSS colitis severity is
known to depend on microbiota, which
varies among research facilities. Instead,
this group tested anti-cytokine agents in
mice that lack the multidrug-resistance
gene Abcb1a and are infected with Heli-
cobacter bilis. In this setting, they found
that blockade of IL-23 improved disease,
whereas blockade of IL-17A or IL-17RA
Figure 1. Dichotomy between Anti-IL-23 Antibody Treatment and Anti-IL-17 Treatment in
Murine Colitis
Blockade of IL-23 ameliorates colitis symptoms in mice, which is associated with reduced expression of
inflammatory cytokines and a concomitant increase in the ratio of Treg cells to Th17 cells. Anti-IL-23
therapy is also linked to improvement in epithelial barrier integrity, including increased amounts of Cldn4
mRNA and re-localization of occludin to the tight junction. Conversely, anti-IL-17 or anti-IL-17R antibody
treatment triggers elevated amounts of cytokines, decreased Treg cell numbers, epithelial barrier
breakdown, and leakiness of lumen contents.
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associated with reduced intestinal barrier
maintenance. This group also assessed
gene expression differences during anti-
body blockade, and found that expres-
sion of claudin 4, a marker of injured
epithelial tissue, was increased in mice
given anti-IL-17RA antibodies.
These papers highlight a facet of IL-17
function that has been underappreciated.
That is, IL-17 is best known as an inducer
of neutrophil-promoting cytokines and
chemokines, such as IL-6, granulocyte
colony-stimulating factor (G-CSF) and
the chemokine CXCL1. IL-17 also acti-
vates expression of antimicrobial pep-
tides (AMPs), including b-defensins, lipo-
calins, and S100A8/9 (also known as
calprotectin). Consistently, Maxwell et al.
showed that expression of b-defensin 1
and S100A8 were reduced following anti-
IL-17RA treatment. However, a surprise
finding was that neutralization of IL-17RA
or IL-17 led to enhanced expression of
cytokines and chemokines. A similar in-
crease in pro-inflammatory factors during
colitis in Il17a/ mice has recently been
reported (Song et al., 2015). Although
intriguing, these are not the first studiesto suggest roles for IL-17 in wound repair
and epithelial maintenance. The connec-
tion of IL-17 to occludin and other genes
associated with epithelial integrity has
been noted in barrier integrity associated
with the cornea as well as for IL-17C in in-
testinal inflammation (Chen et al., 2011;
Reynolds et al., 2012).
The data presented here add to a
growing body of literature showing that
in the gut IL-17 promotes homeostasis
and tissue repair rather than driving path-
ogenic inflammation as it does in psoria-
sis. This begs the obvious question of
what dictates this balance. An attractive
candidate for such a regulator is IL-23.
In this regard, production of IL-17A by
gd-T cells, the primary producers of gut-
protective IL-17A in the DSS model used
by Lee et al., was independent of IL-23,
implying that blockade of IL-23 would
not impair IL-17 production from innate
lymphocytes. Maxwell et al. found that
IL-17A+IFN-g+ CD4+ T cells were associ-
ated with exacerbation of colitis in their
model system (Maxwell et al., 2015).
These ‘‘double-producing’’ T cells have
been implicated in several disease
models, and notably are elevated in the in-Immunity 43flamed mucosa of IBD patients. More-
over, IL-17A+IFN-g+ CD4+ T cells are IL-
23-dependent, regarded as a distinctive
trait of pathogenic Th17 cells (McGeachy
et al., 2007). T regulatory (Tregs) cells
are also associated with protection
against colitis. Indeed, colitis symptoms
upon antibody treatment correlated
closely with changes in Foxp3+ Treg cells
(Lee et al., 2015). Recently, it has been
proposed that Th17 and Treg cells coop-
erate in the gut to promote repair of the
damaged epithelial barrier during colitis
(Song et al., 2015). The two studies pub-
lished in this issue support this emerging
theme.
The data in these complementary
studies, as well as those from Song
et al., help explain the clinical conundrum
that IL-23 blockade is an effective treat-
ment strategy for IBD, whereas targeting
IL-17 is on balance harmful. Some key
questions of course remain. What regu-
lates IL-17 expression in gd-T cells, if
not IL-23? One likely candidate is IL-1b,
which induces IL-17+ gd-T cells in mice.
Why are murine colitis models so vari-
able? The contribution of the intestinal mi-
crobiota is likely to be an important facet
of the intestinal response, and the inter-
play between IL-17 signaling and the mi-
crobiota needs to be explored. IL-17RA
deficiency in humans is associated with
chronic opportunistic Candida albicans
infections, yet there is no apparent
dissemination of C. albicans in patients
treated with anti-IL-17 biologic drugs, at
least so far. It is conceivable that IL-17
signaling might differ on intestinal epi-
thelia compared to other epithelial sur-
faces. It is also possible that these data
raise issues regarding potential adverse
effects of anti-IL-17A therapy in diseases
where IBD exhibits overlap (e.g., celiac
disease and ankylosing spondylitis).
Lastly, IL-22 is another Th17 cell-derived
cytokine that is more commonly viewed
as having a protective role in epithelial tis-
sue. Clearly in these settings IL-22 and IL-
17 are not redundant, but is their function
in any way cooperative (as has been sug-
gested in psoriasis models)?
Most of the constituent elements re-
ported in these papers were already
known, such as the conflict between
IL-23 and IL-17 in colitis, the potential of
IL-17 to drive epithelial repair, and the
idea that gd-T cells can be major sources
of IL-17. Nonetheless, these reports, October 20, 2015 ª2015 Elsevier Inc. 621
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Previewselegantly put these concepts together in a
comprehensive picture that is highly rele-
vant from a clinical standpoint. In other
words, if there’s something strange and
you don’t feel good, who ya gonna call?
IL-23, not IL-17, might be the real Gut-
Buster.
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Whereas dendritic cells (DCs) can be activated in many ways to trigger immunity, hardly anything is known
about the mechanisms that counterbalance DC activation. Cyster and colleagues now demonstrate that the
‘‘self’’ molecule CD47 on erythrocytes critically restricts splenic DC activation.Since the pioneering work on antibodies
by Paul Ehrlich (Ehrlich, 1891) and the
discovery of the ABO blood group sys-
tem by Karl Landsteiner (Landsteiner,
1900), immunology as a science has
come a long way. Over the years, foreign
red blood cells (RBCs) have continued to
be a favorable antigenic agent for
inducing immunity and for studying the
functioning of the immune system. This
was not only because antibody re-
sponses could easily be measured, e.g.,
by Landsteiner’s hemagglutination as-
says, but also because such RBCs
generate robust immune responses
(Kraal et al., 1982). However, the basis
for this strong immunogenicity of foreign
RBCs has remained essentially elusive.
The paper by Yi et al. in this issue of Im-
munity (Yi et al., 2015) describes a series
of elegant experiments that reveal why
xenogeneic RBCs induce such strong
immune responses. The study focuses
primarily on the activation of CD4-posi-
tive dendritic cells (DCs) in the spleen.These CD4+ DCs are known to play a
key role in the activation of CD4 follicular
helper cells and the triggering of the
germinal-center reaction, which in turn
will drive antibody responses. First, it
was demonstrated that immunization of
mice with xenogeneic RBCs (in this
case sheep RBCs), but not with synge-
neic RBCs, stimulated CD4+ DC activa-
tion. Subsequently, the authors turned
their attention to the mechanism underly-
ing this species-specific phenomenon,
and in particular, to the role of interac-
tions between CD47 and the inhibitory
immunoreceptor signal regulatory protein
a (SIRPa), both of which are actually well
known to act in a species-specific
fashion (Barclay and Van den Berg,
2014). CD47 on erythrocytes and other
cells has previously been identified as a
signal of ‘‘self,’’ and the lack of CD47
on RBCs leads to a very rapid clearing
of these cells by macrophages in vivo
(Oldenborg et al., 2000). This is because
CD47 interacts with SIRPa on macro-phages and acts as a ‘‘don’t eat me’’
signal to prevent phagocytosis (Barclay
and Van den Berg, 2014). However,
because CD4+ DCs also express SIRPa,
and because splenic DCs might directly
interact with circulating RBCs in the mar-
ginal zone, where many of these DCs are
localized in the so-called marginal-zone
bridging channels, it was reasoned that
direct CD47 and SIRPa interactions be-
tween these RBCs and DCs, respectively,
might be instrumental in the observed
dampening of DC activation. Indeed, the
injection of CD47-deficient (but not wild-
type) RBCs caused a strong CD4+ DC
activation, and this was accompanied by
migration to and accumulation of these
DCs in the T cell zones of the splenic white
pulp, where they could activate CD4+
T cells (Figure 1). The authors obtained
further evidence that CD47-SIRPa inter-
actions were in fact involved by injecting
blocking antibodies against SIRPa. More-
over, the lack of CD47 on RBCs promoted
the induction of antigen-specific CD4+
